Meibography in clinical practice

Article

Technological advances mean meibography may be used to diagnose MGD

Meibomian gland dysfunction (MGD) is one of the most common causes of an abnormality of the tear film lipid layer and evaporative dry eye.1–5 Numerous risk factors of MGD are reported (Table 1).6 Its prevalence varies between countries from 20% to 60%, with the highest rate in Japan.6 MGD is a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion.7 This may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation and ocular surface disease.7

Meibography is the only clinically in vivo technique to visualize the morphology of the meibomian glands. When using this method, the structure of the meibomian glands, including the ducts and acini, can be observed.8–16 Meibography provides photographic documentation of the meibomian gland under specialized illumination techniques.17 This article is aimed to summarize recent development and investigation in meibography and its clinical relevance.

There are two principles in meibography. One is the transillumination of the everted lid11,18,19 the other is direct illumination, named the non-contact meibography.15,20–22 In the transillumination technique, the eyelid is everted over a light source.11,13,23 The most basic version uses white light, for example from a Finoff transilluminator. This is applied to the cutaneous side of the everted eyelid and allows observation from the palpebral conjunctival surface. Tapie24 was probably first describing evaluation of meibomian glands by transilluminating lids in 1977. He also captured the meibomian glands using infrared film (IR). Jester et al.16 adapted the biosmicroscopic and photographic techniques to improve upon Tapie's technique.16 Subsequently many other groups have used the transillumination IR techniques in meibomian gland observation.11,18,19,25

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.